Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the
trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0
mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects
with type 2 diabetes (T2D) on a background treatment of metformin